<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35411017</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Long COVID occurrence in COVID-19 survivors.</ArticleTitle><Pagination><StartPage>6039</StartPage><MedlinePgn>6039</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6039</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-10051-z</ELocationID><Abstract><AbstractText>This cross-sectional study aimed to investigate the post-acute consequences of COVID-19. We conducted a self-administered questionnaire survey on sequelae, psychological distress (K6), impairments in work performance (WFun), and COVID-19-related experiences of stigma and discrimination in two designated COVID-19 hospitals in Hiroshima Prefecture, Japan, between August 2020 and March 2021. The prevalence of sequelae was calculated by age and COVID-19 severity. Factors independently associated with sequelae or psychological distress were identified using logistic regression analysis. Among 127 patients who had recovered from COVID-19, 52.0% had persistent symptoms at a median of 29&#xa0;days [IQR 23-128] after COVID-19 onset. Among patients with mild COVID-19, 49.5% had sequelae. The most frequent symptoms were olfactory disorders (15.0%), taste disorders (14.2%), and cough (14.2%). Multivariate analysis showed that age was an independent risk factor for sequelae (adjusted odds ratios [AOR] for&#x2009;&#x2265;&#x2009;60&#xa0;years vs.&#x2009;&lt;&#x2009;40&#xa0;years 3.63, p&#x2009;=&#x2009;0.0165). Possible psychological distress was noted in 30.7% (17.9% of males and 45.0% of females). Female sex and the presence of sequelae were independent risk factors for psychological distress. Of all participants, 29.1% had possible impairments in work performance. Experiences of stigma and discrimination were reported by 43.3% of participants. This study revealed the significant impacts of Long COVID on health in local communities. A large-scale, long-term cohort study is desired.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miwata</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitahara</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okimoto</LastName><ForeName>Mafumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kanon</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>E</LastName><ForeName>Bunthen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Payment Certification Agency (PCA), Ministry of Health, Phnom Penh, Cambodia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouoba</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit&#xe9; de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Science de La Sant&#xe9; (IRSS), Nanoro, Burkina Faso.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akita</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanimine</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological and Transplantation Surgery, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohdan</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological and Transplantation Surgery, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kubo</LastName><ForeName>Tatsuhiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Public Health and Health Policy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagasawa</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Miyoshi Central Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakanishi</LastName><ForeName>Toshio</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Miyoshi Central Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takafuta</LastName><ForeName>Toshiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Junko</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. jun-tanaka@hiroshima-u.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Front Immunol. 2024 Mar 04;15:1344086. doi: 10.3389/fimmu.2024.1344086</RefSource><PMID Version="1">38500880</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>12</Day><Hour>5</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35411017</ArticleId><ArticleId IdType="pmc">PMC8996498</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-10051-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-10051-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324:782&#x2013;793. doi: 10.1001/jama.2020.12839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12839</ArticleId><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan. Discharge and other criteria for patients with new coronavirus infection (variants) [in Japanese]. https://www.mhlw.go.jp/content/000776018.pdf (2021).</Citation></Reference><Reference><Citation>The Lancet. Facing up to long COVID. The Lancet396, 1. 10.1016/s0140-6736(20)32662-3 (2020).</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpin SJ, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2021;93:1013&#x2013;1022. doi: 10.1002/jmv.26368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26368</ArticleId><ArticleId IdType="pubmed">32729939</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. (Lond) 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujino Y, et al. Development and validity of a work functioning impairment scale based on the Rasch model among Japanese workers. J. Occup. Health. 2015;57:521&#x2013;531. doi: 10.1539/joh.15-0135-OA.</Citation><ArticleIdList><ArticleId IdType="doi">10.1539/joh.15-0135-OA</ArticleId><ArticleId IdType="pmc">PMC6706181</ArticleId><ArticleId IdType="pubmed">26345178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishimaru T, Mine Y, Fujino Y. Two definitions of presenteeism: Sickness presenteeism and impaired work function. Occup. Med. (Lond) 2020;70:95&#x2013;100. doi: 10.1093/occmed/kqaa009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqaa009</ArticleId><ArticleId IdType="pubmed">32009152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessler RC, et al. Screening for serious mental illness in the general population. Arch. Gen. Psychiatry. 2003;60:184&#x2013;189. doi: 10.1001/archpsyc.60.2.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.60.2.184</ArticleId><ArticleId IdType="pubmed">12578436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan. Comprehensive Survey of Living Conditions [in Japanese]. https://www.mhlw.go.jp/toukei/list/20-21tyousa.html (2019).</Citation></Reference><Reference><Citation>National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann. Intern. Med. 2021;174:576&#x2013;578. doi: 10.7326/M20-5661.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-5661</ArticleId><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi, A., Bernabei, R., Landi, F. &amp; Gemelli Against, C.-P.-A. C. S. G. Persistent symptoms in patients after acute COVID-19. JAMA324, 603&#x2013;605. 10.1001/jama.2020.12603 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021;27:258&#x2013;263. doi: 10.1016/j.cmi.2020.09.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: Results from a prospective UK cohort. Thorax. 2021;76:399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O, et al. Post-acute COVID-19 syndrome: Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Management Section, Disaster Prevention Division, Bureau of General Affairs, Tokyo Metropolitan Government. The 31st Tokyo novel coronavirus infection monitoring conference material (2021 February 4) [in Japanese]. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1009676/1012970.html (2021).</Citation></Reference><Reference><Citation>Sudre CH, et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabavi N. Long covid: How to define it and how to manage it. BMJ. 2020;370:m3489. doi: 10.1136/bmj.m3489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3489</ArticleId><ArticleId IdType="pubmed">32895219</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE. 2020;15:e0240784. doi: 10.1371/journal.pone.0240784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Otte MS, Eckel HNC, Poluschkin L, Klussmann JP, Luers JC. Olfactory dysfunction in patients after recovering from COVID-19. Acta Otolaryngol. 2020;140:1032&#x2013;1035. doi: 10.1080/00016489.2020.1811999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00016489.2020.1811999</ArticleId><ArticleId IdType="pubmed">32852240</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Cruz RF, et al. Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia. ERJ Open Res. 2021;7:1. doi: 10.1183/23120541.00655-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00655-2020</ArticleId><ArticleId IdType="pmc">PMC7585700</ArticleId><ArticleId IdType="pubmed">33575312</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care. 2020;24:422. doi: 10.1186/s13054-020-03120-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03120-0</ArticleId><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ, Pogue A, Hill JM. SARS-CoV-2 infectivity and neurological targets in the brain. Cell Mol. Neurobiol. 2022;42:217&#x2013;224. doi: 10.1007/s10571-020-00947-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-020-00947-7</ArticleId><ArticleId IdType="pmc">PMC7445393</ArticleId><ArticleId IdType="pubmed">32840758</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, et al. Long COVID in the Faroe Islands: A longitudinal study among nonhospitalized patients. Clin. Infect. Dis. 2021;73:e4058&#x2013;e4063. doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Goertz YMJ, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:1. doi: 10.1183/23120541.00542-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, et al. Post-COVID-19 symptom burden: What is long-COVID and how should we manage it? Lung. 2021;199:113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Okawara M, et al. Association between the course of hypnotics treatment for insomnia and work functioning impairment in Japanese workers. PLoS ONE. 2020;15:e0243635. doi: 10.1371/journal.pone.0243635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243635</ArticleId><ArticleId IdType="pmc">PMC7728191</ArticleId><ArticleId IdType="pubmed">33301520</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasoni D, et al. Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan Italy. J. Med. Virol. 2021;93:1175&#x2013;1179. doi: 10.1002/jmv.26459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26459</ArticleId><ArticleId IdType="pmc">PMC7461061</ArticleId><ArticleId IdType="pubmed">32841387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza MG, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav. Immun. 2020;89:594&#x2013;600. doi: 10.1016/j.bbi.2020.07.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.07.037</ArticleId><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain SR, Grant JE, Trender W, Hellyer P, Hampshire A. Post-traumatic stress disorder symptoms in COVID-19 survivors: online population survey. BJPsych Open. 2021;7:e47. doi: 10.1192/bjo.2021.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjo.2021.3</ArticleId><ArticleId IdType="pmc">PMC7873456</ArticleId><ArticleId IdType="pubmed">33557964</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62,354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130&#x2013;140. doi: 10.1016/S2215-0366(20)30462-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30462-4</ArticleId><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 2021;27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Labour and Welfare, Japan. Overview of 2019 Comprehensive Survey of Living Conditions [in Japanese]. https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa19/index.html (2019).</Citation></Reference><Reference><Citation>Bagcchi S. Stigma during the COVID-19 pandemic. Lancet Infect. Dis. 2020;20:782. doi: 10.1016/S1473-3099(20)30498-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30498-9</ArticleId><ArticleId IdType="pmc">PMC7314449</ArticleId><ArticleId IdType="pubmed">32592670</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A guide to preventing and addressing social stigma. https://www.who.int/docs/default-source/coronaviruse/covid19-stigma-guide.pdf (2020).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>